In a single-center observational study of 3195 CKD patients with an eGFR of 10–60 mL/min/1.73 m2, the rate of initiation of renal replacement therapy was significantly lower in patients treated with MR antagonists than in those treated without MR antagonists [179], with a hazard ratio of 0.72, which also suggests that the use of MR antagonists is associated with improved kidney outcome. Here, NR3C2 is linked to chronic kidney disease.